Abstract
Cancer patients coming to operation can suffer from multiple systenuc problems which may complicate the anaesthetic management. Interactions between anaesthetics and cytotoxic agents can occur. Patients may have increased sensitivity to general anaesthetics, and prolonged neuromuscular blockade might occur after muscle relaxants.
Article PDF
Similar content being viewed by others
Avoid common mistakes on your manuscript.
References
Cline, M.J. &Haskell, C.M. Cancer Chemotherapy, third edition, Philadelphia, W.B. Saunders (1980).
Des Regato, J.A. &Spjut, H.J. Cancer: diagnosis, treatmem and prognosis, fifth edition, St. Louis, C.V. Mosby (1977).
Goodman, L.S. &Gillman, A. The pharmacological basis of therapeutics, fifth edition, New York, Macmillan (1975).
Mills, B.A. Cyclophosphamide induced eardiomyopathy. Cancer43 (6), 2223–6 (1979).
von Hoff, D.D., Reichert, C.M., Reddick, R.L., Rozencweig, M., Young, R.C. &Maggia, F.M. Toxic effects of cis-Dichlorodiammeplatinum in Man. Cancer treatment reports63: 1527–1531 (1979).
Mason, J.W. Anthracyeline eardiotoxicity — recognition, management and avoidance. Comprehensive therapy5:64–68 (1979).
Cartes, S.K. Adriamycin — A review. J. of the National Cancer Inst.55:1265–74 (1975).
Von Hoff, D.D.,et al. Risk factors for Doxorubicin-induced congestive heart failure. Ann. of Int. Med.91:710–717 (1979).
Choe, J.Y., Combs, A.B. &Folkers, K. Potentiation of the toxicity of adriamycin by propranolol. Research communications in Chemical Pathology and Pharmacology 21:578–580 (1978).
Minow, R.A., Benjamin, R.S. &Gottlieb, J.A. Adriamycin cardiomyopathy — an overview with determination of risk factors. Cancer Chemother Rep. 6:192–200 (1975).
Rinehart, J., Lewis, R. &Balcerzak S.P. Adriamycin cardiotoxicity in man. Ann Int. Med.81:475–8 (1974).
Jones, S.E., Ewy, G.A. &Groves, B.M. Echocardiographic detection of adriamycin heart disease. Proc. Am. Assoc. Cancer Res.16:228 (1975).
Hankins, D.G., Macdonald, F.M. &Drage, C.W. Pulmonary toxicity recurring after a six week cause of busulfan therapy and after subsequent therapy with uracil mustard. Chest73:415 (1978).
Patel, H.R., Shah, P.C., Rhee, H.L., Sassoon, H. &Rao, K. P. Cyclophosphamide therapy and interstitial pulmonary fibrosis. Ca.38: 1542–9 (1976).
Cole, S.R., Myers, T.J. &Klatsky, A.V. Pulmonary disease with chlorambucil Therapy, Ca.41:45509 (1978).
Nesbit, M., Krivit, W., Heyn, R. &Sharp, H. Acute and chronic effects of methotrexate on hepatic, pulmonary and skeletal system. Cancer37:1048–1054 (1976).
Dukes, M.N.G. Side effects of Drugs Annual I, 9th Edition, Amsterdam, Excerpta Media.
Crooke, S.T. &Bradner, W.T. Bleomycin: A review. J. Med. 7:333–428 (1976).
Dewys, W. Working conference on anorexia and cachexia of neoplastic disease. Cancer Res.30: 2816–2818 (1970)
Livingston, R.B. &Carter, S.K. Single agents in cancer chemotherapy. New York, Plenum Publishing Corp. (1970).
McIlvanie, S.K. &MacCarthy, J.D, Hepatitis in association with prolonged 6 mercaptopurine therapy. Blood 14:80–90 (1959).
Slavin, R.E., Millan, J.C. &Mullins, G.M. Pathology of high dose intermittent cyclophosphamide therapy. Hum. Pathol.6:693–709 (1975).
Hersh, E.M., Wono, V.G., Henderson, E.S. &Fremeich, E.J. Hepatotoxic effects of methotrexate. Cancer19:600–606 (1966).
Kennedy, B.J. Metabolic and toxic effects of mithramycin during tumour therapy. Am. J. Med.49:494–503 (1970).
Capizz, R.L., Bertino, J.R. &Handschumacher, R.E. L-Asparaginase. Ann. Rev. Med.21:433–44 (1970).
Broder, L.E. &Carter, S.K. Pancreatic islet cell carcinoma 1I. Results of therapy with streptozotocin in 50% patients. Ann. Intern Med.79: 108–18 (1973).
Condit, P.T., Chanes, R.E. &Joel, W. Renal toxicity of Methotrexate. CA.23:126–31 (1969).
Silver, R.T., Lauper, R.D. &Jarowski, C.I. A synopsis of cancer chemotherapy, New York, Dun Donnelley (1977).
Schein, P.S., O’Connell, M.J., Blom,et al. Clinical antitumour activity and toxicity of streptozotocin. Cancer34:993–1000 (1974).
Sartorelli, A.C. &Johns, D.G. Antineoplastic and immunosuppressive agent. Part I, New York, Springer-Verlag (1974).
Harris, J.E. &Sinkovics, J.G. The inununology of malignant disease. 2nd edition, St. Louis, C.V. Mosby (1976).
Peck, S.D. &Reiquam, C.W. Disseminated intravascular coagulation in cancer patients: Supportive evidence. Cancer31:1114–1119 (1973).
Goodnight, S. H. Jr. Bleeding and intravascular clotting in malignancy: a review. Ann. N.Y. Acad. Sci.230:271–288 (1974).
Monto, R.W., Talley, R.W., Caldwell, M.J., Levin, W.C. &Guest, M.M. Observations on the mechanism of haemorhagic toxicity in mithramycin toxicity. Can. Res.29:697–700 (1969).
Marks, L.J., Steinke, J., Podolsky, S.,et al. Hypoglycaemia associated with neoplastic. Ann. N.Y. Acad. Sci.230:147–160 (1974).
Silva, O.L., Becker, K.L., Primack, A.,et al. Ectopic production of calcitonin by oat cell carcinoma. N.E.J.M.290:1122–1124 (1974).
Hall, T.C., Griffiths, C.T. &Petranek, Jr. Hypocalcaemia — an unusual metabolic complication of breast cancer. N.E.J.M.275: 1474–1477 (1966).
Singer, F.R., Bethune, J.E. &Massry, S.G. Hypercalcaemia and hypocalcaemia. Clini. Nephrol.7:154–162 (1977).
Chisholm, G.D. Nephrogenic ridge turnouts and theft syndromes. Ann. N.Y. Acad. Sci.230: 403–423 (1974).
Stolinsky, D.C. Paraneoplastic syndromes. West. J. Med.132:189–208 (1980).
Dyck, P.J., Thomas, P.K. &Lambert, E.H. Peripheral neuropathy. Philadelphia, W.B. Saunders (1975).
Tyler, H.R. Paraneoplastic syndromes of nerve, muscle and neuromuscular junction. Ann. N.Y. Acad. Sci.230:348–357 (1974).
Weiss, H.D., Walker, M.D. &Wiernik, P.H. Neurotoxicity of commonly used antineoplastic agents. N.E.J.M.291:75–81 (1974).
Kedar, A., Cohen, M.E. &Freeman, A.I. Peripheral neuropathy as a complication of cis-Dichlorodiammine-platinum treatment: a case report. Cancer treatment reports.62:819–821 (1978).
Siemsen, J.K. &Meister, L. Bronchogenic carcinoma associated with severe orthostatic hypotension. Ann. Int. Med.58:669–676 (1963).
Eaton, L.M. &Lambert, E.H. Electromyography and electric stimulation of nerves in diseases of motor unit. J.A.M.A.163:1117–1124 (1957).
Fukuhara, N., Tekamori, M., Gutmann, I.,et al. Eaton-Lambert syndrome: Ultrastructural study of the motor end-plates. Arch. Neurol.27: 67–78 (1972).
Lipton, A., Hepner, G.W., White, D.S. &Harvey, H.A. Decreased hepatic drug demethylation in patients receiving chemotherapy. Cancer41:1680–84 (1978).
Mosedale, B. &Smith, M.A. Corynebacterium parvum and anaesthetics. Lancet1 (7899): 168 (1975).
Wetstone, H.J., Lamotta, R.V.,et al. Studies of cholinesterase activity, V. Serum cbolinestgrase in patients with carcinoma. Annals Int. Med.52:102–125 (1960).
Mone, J.G. &Mathrie, W.E. Qualitative and quantitative defects of pseudocholinesterase activity. Anaesthesia22:55–68 (1967).
Walker, I.R., Zapf, P.W. &Mackay, I.R. Cyclophosphamide, cholinesterase and anaesthesia, Aust. N.Z. J. Med.3:247–251 (1972).
Gurman, G.M. Prolonged apnoea after succinylcholine in a case treated with cystostatics for cancer. Anaes. Analgesia.51:761–765 (1972).
Wang, R. &Ross, C.A. Prolonged apnoea following succinylcholine in cancer patients receiving AB 132. Anaesthesiology24:363–367 (1963).
Zaigmond, E.K. &Robins, G. The effects of a series of anticancer drugs on plasma cholinester-use activity. Can. Anaesth. Soc. J.19:75–82 (1972).
Vetten, K.B. Immunosuppressive therapy and anaesthesia. S.A. Med. J.47:767–770 (1973).
Bennett, E.J.,Schmidt, G.B., Patel, K.P. &Grundy, E.M. Muscle relaxants, myasthenia, and mustards. Anesthesiology46:220–221 (1977).
Clement, J.G. &Colhoun, E.H. Presynaptic effects of the aziridinium ion of acetycholine mustard on the phrenic nerve rat diaphragm preparation. Can. J. Physiol. Pharmacol.53: 264–272 (1975).
Colhoun, E.H. &Rylett, B.J. Further facts about neuromuscular blockade by nitrogen mustard and by thiotepa. Anaesthesiology48:381 (1978).
Hoosten, P.D. Drag interactions. Fourth edition, Philadelphia, Lea and Febriger (1979).
Mann, A.M. &Hutchison, J.L. Manic reaction associated with procarbazine hydrochloride therapy of Hodgkin’s disease. Can. Med. Assoc. J.97:1350 (1967).
Goldiner, P.L., Carlon, G.C., Critkovic, E., Schweizer, O. &Howland, W.S. Factors influencing postoperative morbidity and mortality in patient treated with bleomycin. Brit. Med. J.1: (6128): 1664–7 (1978).
Goldiner, P.L. &Schweizer, O. The hazards of anaesthetics and surgery in bleomycin-treated patients. Seminars in Oncology6:121–124 (1979).
Author information
Authors and Affiliations
Rights and permissions
About this article
Cite this article
Chung, F. Cancer, chemotherapy and anaesthesia. Can. Anaesth. Soc. J. 29, 364–371 (1982). https://doi.org/10.1007/BF03007527
Issue Date:
DOI: https://doi.org/10.1007/BF03007527